Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Half-dose Sugammadex vs Neostigmine for Rocuronium Reversal in Laparoscopic Cholecystectomy
NCT06794450Phase 2
Key facts
- Status
- Recruiting
- Start
- Nov 2024
- Primary completion
- Feb 2025
- Countries
- 1
- Sponsor
- Universitas Padjadjaran
- Modality
- Biodegradable Polymers, Small Molecules
- Drugs
- Sugammadex
- Conditions
- neuromuscular blockade (NMB)
01
Overview
Phase 2, randomised trial of Sugammadex in neuromuscular blockade (NMB) (2 arms), sponsored by Universitas Padjadjaran. Primary endpoint: Recovery time at 1 hour. Started Nov 2024; status: recruiting.
02
Design
2 arms- Study design
- Randomized
Sugammadex
Sugammadex 1 mg/kg IV
Neostigmine
Neostigmine 60 mcg/kg + Atropine IV
03
Who it enrols
Adult patients (18-59 years) with ASA status 1 or 2 undergoing laparoscopic cholecystectomy under general anesthesia with rocuronium. Excludes patients with renal dysfunction, musculoskeletal or CNS disorders, drug allergies, or difficult airways.
04
Endpoints
Primary
Recovery time
Secondary
Spontaneous recovery time of rocuronium
Bradycardia
Hypotension
Beyond the preview
Go deeper on NCT06794450.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06794450.